Acadian Asset Management’s TransCode Therapeutics RNAZ Stock Holding History

Acadian Asset Management’s Portfolio RNAZ Stock Details RNAZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-797	Closed	-$11K	–	1807
2025 Q1	$11K	Buy	+797	New	+$102K	﹤0.01%	1554

Other funds holding RNAZ

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SouthState Corp Winter Haven, Florida $2.4B AUM 23.05% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Acadian Asset Management's RNAZ Position: Q2 2025 in Review

Acadian Asset Management sold out of TransCode Therapeutics (RNAZ) in Q2 2025, closing a stake of 797 shares — an estimated $11K sold.

Acadian Asset Management first reported a position in RNAZ in Q1 2025 and held it in 1 quarter. The position peaked at $11K in Q1 2025. 9 funds tracked by Wall St. Rank hold RNAZ as of Q2 2025.

Acadian Asset Management reported no remaining TransCode Therapeutics position as of Q2 2025 after selling out during the quarter.
Acadian Asset Management sold 797 TransCode Therapeutics shares in Q2 2025, an estimated $11K.
Acadian Asset Management first reported a position in TransCode Therapeutics in Q1 2025 and held it in 1 quarter.
Acadian Asset Management's TransCode Therapeutics position peaked at $11K in Q1 2025.
9 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2025.

Based on Acadian Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.